Printer Friendly

Hormone therapy use posited to reduce cartilage turnover.

CHICAGO -- Current hormone therapy use in postmenopausal women reduces cartilage turnover, according to evidence from levels of a biomarker in the blood-stream, Joanne M. Jordan, M.D., reported at the 2004 World Congress on Osteoarthritis.

The study included an ethnically diverse sample of 168 postmenopausal women from the Johnston County (N.C.) Arthritis Project; 49% were African American, 23% were current hormone therapy (HT) users, and 63% had knee osteoarthritis (OA).

Rates of type II collagen cleavage, as measured by levels of the cartilage degradation assay, and collagen II synthesis, as measured by type II procollagen (CPII) synthesis, were lower in current HT users than in nonusers (P = .032 and P < .001, respectively).

Taken together, these results demonstrate reduced collagen II turnover in HT users, both with and without osteoarthritis, Dr. Jordan reported in a poster presentation at the meeting, sponsored by the Osteoarthritis Research Society International.

Dr. Jordan and colleagues at the Thurston Arthritis Research Center at the University of North Carolina at Chapel Hill previously reported that current HT use is associated with lower levels of serum cartilage oligomeric matrix protein, another marker of cartilage degradation.

The current study, led by doctoral student Anca D. Dragomir, included women who themselves reported using hormone pills, shots, or implants. Knee osteoarthritis was defined as those patients with a knee Kellgren-Lawrence grade of 2 or more.

In a separate analysis, after controlling for ethnicity, age, body mass index, and knee OA status, only the reduction in mean CPII associated with current HT use remained significantly associated with collagen II synthesis.

However, there was evidence of an association between current HT use and knee OA status for another biomarker, chondroitin sulphate epitope 846 (CSE 846), thought to be a marker of newly synthesized cartilage proteoglycan. HT users without OA had higher levels of CSE 846, compared with HT users with OA.

This suggests that HT use could increase proteoglycan aggrecan production in postmenopausal women with no radiographic evidence of knee or hip OA.
COPYRIGHT 2005 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Rheumatology
Publication:Internal Medicine News
Geographic Code:1USA
Date:Mar 15, 2005
Previous Article:Composite MRI evaluation more telling of knee OA pathology.
Next Article:Safer way to curb local breast Ca recurrences.

Related Articles
History of HRT benefits breast cancer patients. (Lower Incidence of Bone Metastases).
Study results have left many women confused about hormone therapy. (Digest).
Selena trial: hormone therapy tied to mild lupus flares.
Alexander, J.L., Kotz, K., Dennerstein, L. et al. (2004). The effects of postmenopausal hormone therapies on female sexual functioning: a review of...
Health, fractures guide bisphosphonate decision.
PPIs prescribed along with NSAIDs almost 50% of time.
Osteoarthritis in 2007.
Existing osteoporosis drug may keep joint injuries from causing long-term osteoarthritis.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters